Anlon Healthcare
14.71
+0.10(+0.68%)
Market Cap₹781.86 Cr
PE Ratio22.84
IndustryHealthcare
Company Performance:
1D+0.68%
1M-8.01%
6M+21.47%
1Y-83.96%
5Y-83.96%
View Company Insightsright
More news about Anlon Healthcare
07Jul 26
Anlon Healthcare CMD outlines growth strategy in interview
Anlon Healthcare Limited's Chairman & Managing Director, Mr. Punitkumar Rasadia, participated in an interview on July 06, 2026, to discuss business performance, industry outlook, and growth strategy. The interview covered operational updates, capital expenditure, acquisition possibilities, and financial guidance without sharing unpublished price sensitive information.
 no imag found
02Jul 26
Anlon Healthcare approves two new subsidiaries to expand portfolio
Anlon Healthcare Ltd approved the incorporation of two new subsidiaries, Anlon Medicare Private Limited and Anlon Biologics Private Limited, on July 1, 2026, with a total investment of ₹17.5 lakh. The company will hold a 55% stake in Anlon Medicare to manufacture surgical implants and a 65% stake in Anlon Biologics for peptides and biosimilars. Additionally, the Board approved renaming Remember India Health Links Private Limited to Anlon Medicos Private Limited, subject to regulatory approvals.
 no imag found
26Jun 26
Anlon Healthcare reports Q1FY26 net profit of ₹354.69 lakh
Anlon Healthcare reported a net profit of ₹354.69 lakh for Q1FY26 with revenue of ₹3,329.72 lakh. The board approved the unaudited results on November 11, 2025. Total assets increased to ₹19,775.76 lakh as of June 30, 2025.
 no imag found
12Jun 26
Anlon Healthcare CMD to discuss FY26 on NDTV Profit
Anlon Healthcare Limited announced that its Chairman & Managing Director, Mr. Punitkumar Rasadia, will appear on NDTV Profit on June 11, 2026, at 01:30 P.M. IST. The interview will cover the company's growth journey, recent developments, and financial performance for FY 2025-26. The company confirmed that no unpublished price-sensitive information will be shared.
 no imag found
10Jun 26
Anlon Healthcare FY26 PAT rises 42% to ₹29.09 crore
Anlon Healthcare reported a 42.98% YoY rise in consolidated total income to ₹172.22 crore for FY26, with PAT growing 41.77% to ₹29.09 crore. EBITDA increased 47.55% to ₹47.77 crore. The company completed acquisitions of Apiqo Organics and Bizotic Life Science, expanding capacity to 1400-1600 MTPA. Management guided for FY27 revenue of ₹380-400 crore and expects to be cash flow positive by FY27-end.
 no imag found
04Jun 26
Anlon Healthcare FY26 PAT rises 42% to ₹29.09 crore
Anlon Healthcare reported a 42.98% rise in consolidated total income to ₹172.22 crore for FY26, with net profit increasing to ₹29.09 crore. Q4FY26 total income stood at ₹50.90 crore. The company highlighted strategic acquisitions and capacity expansion in its investor presentation.
 no imag found
Anlon Healthcare
14.71
+0.10
(+0.68%)
1 Year Returns:-83.96%
Industry Peers
Sun Pharmaceutical
1,963.50
(-1.36%)
Divis Laboratories
8,585.00
(+6.57%)
Torrent Pharmaceuticals
5,050.00
(-1.42%)
Cipla
1,474.40
(+0.08%)
Zydus Life Science
1,121.00
(-0.51%)
Lupin
2,393.00
(-0.91%)
Mankind Pharma
2,483.00
(+0.54%)
Dr Reddys Laboratories
1,180.00
(+2.78%)
Laurus Labs
1,811.40
(-0.26%)
Aurobindo Pharma
1,554.70
(-1.61%)